Rigel Pharmaceuticals (Nasdaq: RIGL) reported results of the Phase 2 clinical trial of R788 (fostamatinib disodium) in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE